Cancer Research Institute shared a post on LinkedIn:
“Focused ultrasound and cancer immunotherapy are leading the charge to develop safer and more efficient combination therapies.
These cutting-edge technologies are proving to be pivotal, and are offering new hope for improved outcomes for patients.
Recently, CRI’s CEO and Director of Scientific Affairs, Dr. Jill O’Donnell-Tormey, joined Focused Ultrasound Foundation’s podcast, Curing with Sound, to explore the future of cancer immunotherapy and its integration with focused ultrasound. Discover“